

Ral J Andrade

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3144786/raul-j-andrade-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

9,758
citations

47
h-index

95
g-index

210
ext. papers

11,791
ext. citations

5.5
avg, IF

5.96
L-index

#	Paper	IF	Citations
176	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.. <i>Journal of Hepatology</i> , 2022 ,	13.4	1
175	A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury.. <i>Hepatology</i> , 2022 ,	11.2	9
174	Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?. <i>Gastroenterology Report</i> , 2022 , 10, goac014	3.3	1
173	Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. <i>Antioxidants</i> , 2022 , 11, 897	7.1	1
172	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
171	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 3685-3726	15.5	3
170	Long-term sequelae of drug-induced liver injury. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
169	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. <i>Liver International</i> , 2021 , 41, 1523-1531	7.9	3
168	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. <i>Antioxidants</i> , 2021 , 10,	7.1	11
167	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. <i>Drug Safety</i> , 2021 , 44, 619-634	5.1	2
166	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. <i>Archives of Toxicology</i> , 2021 , 95, 1793-1803 ^{5.8}	5.8	2
165	Serious liver injury induced by Nimesulide: an international collaborative study. <i>Archives of Toxicology</i> , 2021 , 95, 1475-1487	5.8	3
164	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
163	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021 , 41, 2076-2086	7.9	5
162	Safety of treating acute liver injury and failure. <i>Expert Opinion on Drug Safety</i> , 2021 , 1-13	4.1	2
161	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. <i>Liver International</i> , 2021 , 41, 2671-2680	7.9	2
160	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. <i>Phytotherapy Research</i> , 2021 , 35, 6-19	6.7	6

159	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1125-1135	6.1	12
158	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <i>Drug Safety</i> , 2021 , 44, 133-165	5.1	4
157	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1147-1158	6.1	5
156	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 153-169	5.5	8
155	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
154	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021 , 164, 105404	10.2	9
153	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021 , 75, 86-97	13.4	18
152	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. <i>Journal of Hepatology</i> , 2021 , 75, 333-341	13.4	6
151	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1604-1612	6.1	1
150	Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. <i>Journal of Hepatology</i> , 2021 , 75, 935-959	13.4	10
149	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020 , 73, 17-25	13.4	26
148	Systematic review: ibuprofen-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 603-611	6.1	14
147	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <i>Liver International</i> , 2020 , 40, 6-17	7.9	16
146	Genetic Predisposition to Drug-Induced Liver Injury. <i>Clinics in Liver Disease</i> , 2020 , 24, 11-23	4.6	12
145	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020 , 94, 3381-3407	5.8	40
144	Drug-induced liver injury in older people. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 862-874	18.8	20
143	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 31-41	18.8	43
142	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46

141	Drug-Induced Liver Injury After Liver Transplantation. <i>Liver Transplantation</i> , 2020 , 26, 1167-1176	4.5	3
140	Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 58	51.1	148
139	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 245-253	6.1	35
138	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 1028-1036	6.1	34
137	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. <i>Gastroenterology</i> , 2019 , 156, 2230-2241.e8	33.4	84
136	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. <i>Seminars in Liver Disease</i> , 2019 , 39, 381-394	7.3	14
135	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019 , 7, 825-837	5.3	11
134	EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , 2019 , 70, 1222-1261	13.4	327
133	Next-Generation Sequencing of Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019 , 10, 134	4.5	7
132	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). <i>Clinical Liver Disease</i> , 2019 , 13, 51-57	2.2	14
131	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019 , 156, 1707-1716.e2	13.3	59
130	Reply letter to "Editorial: bodybuilders beware". <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 473	6.1	
129	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. <i>Gastroenterology</i> , 2019 , 157, 552-568	13.3	39
128	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r + dasabuvir + ribavirin in patients monoinfected with chronic hepatitis C or coinfecting with human immunodeficiency virus-1 in Spain. <i>PLoS ONE</i> , 2019 , 14, e0225061	3.7	3
127	Landscape of Liver Injury From Herbal and Dietary Supplements in Europe, Latin America, and Asia. <i>Clinical Liver Disease</i> , 2019 , 14, 49-50	2.2	2
126	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. <i>Current Pharmaceutical Design</i> , 2019 , 25, 3855-3871	3.3	8
125	Drug-Induced Liver Disease: Mechanism and Diagnosis 2019 , 715-728		1
124	Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. <i>Hepatology</i> , 2019 , 69, 760-773	11.2	114

123	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury. <i>Journal of Pathology</i> , 2019 , 247, 110-122	9.4	3
122	The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. <i>Liver International</i> , 2019 , 39, 401-410	7.9	9
121	Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018 , 38, 21-40	7.3	24
120	Scientific opinion on the safety of green tea catechins. <i>EFSA Journal</i> , 2018 , 16, e05239	2.3	66
119	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1495-1502	6.9	55
118	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018 , 68, 940-948	13.4	12
117	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. <i>Methods in Pharmacology and Toxicology</i> , 2018 , 477-496	1.1	1
116	Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 795-804	4.1	21
115	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 292-294	6.9	11
114	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1260-1270	6.1	43
113	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018 , 155, 1120-1127.e4	13.3	47
112	Chronic liver injury induced by drugs and toxins. <i>Journal of Digestive Diseases</i> , 2018 , 19, 514-521	3.3	16
111	The pro-/anti-inflammatory effects of different fatty acids on visceral adipocytes are partially mediated by GPR120. <i>European Journal of Nutrition</i> , 2017 , 56, 1743-1752	5.2	26
110	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. <i>American Journal of Gastroenterology</i> , 2017 , 112, 384-385	0.7	2
109	Drug-induced liver injury: recent advances in diagnosis and risk assessment. <i>Gut</i> , 2017 , 66, 1154-1164	19.2	250
108	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017 , 152, 1078-1089	13.3	137
107	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017 , 16, 286-292	1	1
106	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017 , 12, e0189436	3.7	11

105	Drug-induced liver and skin reactions: In need of a consensus definition. <i>Hepatology</i> , 2017 , 65, 391	11.2	3
104	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. <i>Liver International</i> , 2017 , 37, 132-140	7.9	22
103	A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017 , 12, e0173914	3.7	18
102	Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1463-1475	4.1	18
101	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. <i>Drug Safety</i> , 2016 , 39, 925-43	5.1	19
100	Creating an effective clinical registry for rare diseases. <i>United European Gastroenterology Journal</i> , 2016 , 4, 333-8	5.3	22
99	"Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge". <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 589-93	5.5	13
98	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 537	6.3	88
97	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 313	6.3	40
96	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	54
95	Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016 , 7, 267	5.6	43
94	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016 , 7, 280	5.6	
93	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 414-22	1.9	15
92	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1611-8	4	17
91	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. <i>Liver International</i> , 2016 , 36, 302-10	7.9	29
90	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016 , 65, 532-42	13.4	82
89	Characterizing Drug-Induced Liver Injury With Autoimmune Features. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1844-1845	6.9	6
88	Drug-induced liver injury: Interactions between drug properties and host factors. <i>Journal of Hepatology</i> , 2015 , 63, 503-14	13.4	231

87	The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015 , 35, 2474-82	7.9	31
86	Reply: To PMID 24704526. <i>Gastroenterology</i> , 2015 , 148, 452-3	13.3	
85	Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?. <i>Journal of Hepatology</i> , 2015 , 62, 751-2	13.4	21
84	Use of HyG law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. <i>Gastroenterology</i> , 2014 , 147, 109-118.e5	13.3	186
83	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <i>Annals of Hepatology</i> , 2014 , 13, 231-239	3.1	25
82	Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. <i>Seminars in Liver Disease</i> , 2014 , 34, 145-61	7.3	23
81	Reply: To PMID 24704526. <i>Gastroenterology</i> , 2014 , 147, 1442	13.3	
80	Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. <i>Drug Safety</i> , 2014 , 37 Suppl 1, S19-31	5.1	26
79	Mechanisms of drug-induced liver injury. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014 , 14, 286-92	3.3	73
78	Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. <i>PLoS ONE</i> , 2014 , 9, e94675	3.7	15
77	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. <i>World Journal of Hepatology</i> , 2014 , 6, 160-8	3.4	69
76	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <i>Annals of Hepatology</i> , 2014 , 13, 231-9	3.1	6
75	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 356-63	3.1	12
74	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. <i>Liver International</i> , 2013 , 33, 1378-85	7.9	32
73	Causality Assessment 2013 , 287-302		1
72	HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. <i>PLoS ONE</i> , 2013 , 8, e68111	3.7	66
71	Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. <i>Frontiers in Pharmacology</i> , 2012 , 3, 2	5.6	10
70	Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. <i>Frontiers in Genetics</i> , 2012 , 3, 253	4.5	11

69	Metformin-induced hepatotoxicity. <i>Diabetes Care</i> , 2012 , 35, e21	14.6	32
68	Plasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 328-33	3	5
67	Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012 , 104, 282-4	0.9	8
66	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. <i>Gastroenterology</i> , 2011 , 141, 338-47	13.3	359
65	Causality assessment methods in drug induced liver injury: strengths and weaknesses. <i>Journal of Hepatology</i> , 2011 , 55, 683-691	13.4	130
64	Drug-induced autoimmune-like hepatitis: a diagnostic challenge. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2501-2; author reply 2502-3	4	12
63	Continuous reporting of new cases in Spain supports the relationship between Herbalife products and liver injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 1080-7	2.6	30
62	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. <i>Hepatology</i> , 2011 , 54, 931-9	11.2	199
61	Hepatic safety of antibiotics used in primary care. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1431-46	4.6	118
60	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 817-28	5.5	38
59	Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. <i>Current Drug Safety</i> , 2010 , 5, 212-22	1.4	21
58	Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in Vigibase: unified list based on international collaborative work. <i>Drug Safety</i> , 2010 , 33, 503-22	5.1	110
57	Sertraline hepatotoxicity: report of a case and review of the literature. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1806-7	4	14
56	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010 , 52, 303-12	11.2	85
55	Drug Induced Liver Disease: Mechanisms and Diagnosis 2010 , 771-786		0
54	Rechallenge in drug-induced liver injury: the attractive hazard. <i>Expert Opinion on Drug Safety</i> , 2009 , 8, 709-14	4.1	38
53	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. <i>Clinical Therapeutics</i> , 2009 , 31, 1014-9	3.5	19
52	Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. <i>Hepatology</i> , 2009 , 49, 2001-9	11.2	221

51	Reply: <i>Hepatology</i> , 2009 , 49, 1777-1779	11.2	
50	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009 , 50, 1702-8	11.2	110
49	Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009 , 10, 1467-87	2.6	80
48	Pharmacogenomics in drug induced liver injury. <i>Current Drug Metabolism</i> , 2009 , 10, 956-70	3.5	61
47	Assessment of drug-induced liver injury in clinical practice. <i>Fundamental and Clinical Pharmacology</i> , 2008 , 22, 141-58	3.1	54
46	Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008 , 48, 721-7	13.4	158
45	Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008 , 49, 107-14	13.4	63
44	Idiosyncratic drug hepatotoxicity: a 2008 update. <i>Expert Review of Clinical Pharmacology</i> , 2008 , 1, 261-76	3.8	14
43	Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. <i>Hepatology</i> , 2008 , 47, 810-6	11.2	39
42	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008 , 48, 588-96	11.2	162
41	Statins: Hepatic Disease and Hepatotoxicity Risk 2008 , 2, 18-23		3
40	Genetic and molecular factors in drug-induced liver injury: a review. <i>Current Drug Safety</i> , 2007 , 2, 97-112	1.4	20
39	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. <i>Hepatology</i> , 2006 , 44, 850-6	11.2	121
38	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006 , 44, 1581-8	11.2	223
37	Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfecting patients with decompensated cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 1236-41	1.6	17
36	Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. <i>Gastroenterology</i> , 2006 , 131, 451-60	13.3	311
35	Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. <i>World Journal of Gastroenterology</i> , 2006 , 12, 5244-6	5.6	16
34	Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?. <i>World Journal of Gastroenterology</i> , 2006 , 12, 5078-80	5.6	9

33	Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. <i>Antiviral Therapy</i> , 2006 , 11, 491-8	1.6	3
32	Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. <i>Gastroenterology</i> , 2005 , 129, 512-21	13.3	681
31	HLA-C and KIR genes in hepatitis C virus infection. <i>Human Immunology</i> , 2005 , 66, 1106-9	2.3	38
30	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. <i>Gastroenterology</i> , 2005 , 128, 636-41	13.3	607
29	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005 , 129, 512-521	13.3	554
28	The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 59-63	2.2	14
27	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005 , 41, 779-89	11.2	214
26	Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 1540-1	2.9	17
25	Serum immunological profile in patients with chronic autoimmune cholestasis. <i>American Journal of Gastroenterology</i> , 2004 , 99, 2150-7	0.7	17
24	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004 , 39, 1603-12	11.2	120
23	Causality assessment in drug-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2004 , 3, 329-44	4.1	59
22	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 71-6	2.8	21
21	Acute leukemia after infliximab therapy. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2577	0.7	7
20	Antidepressant-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2003 , 2, 249-62	4.1	63
19	Lansoprazole-induced hepatic dysfunction. <i>Annals of Pharmacotherapy</i> , 2003 , 37, 1731	2.9	4
18	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 435-40	2.8	58
17	Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 304-8	4	2
16	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 887-90	2.2	36

15	Chronic hepatitis C, ibuprofen, and liver damage. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1854-50.7		14
14	Acute fulminant hepatitis after treatment with rabeprazole and terbinafine: is rabeprazole the culprit?. <i>Archives of Internal Medicine</i> , 2002 , 162, 360-1		7
13	Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 1416-9	4	9
12	Comparison of two clinical scales for causality assessment in hepatotoxicity. <i>Hepatology</i> , 2001 , 33, 123-30.2		181
11	Benzylpenicillin-induced prolonged cholestasis. <i>Annals of Pharmacotherapy</i> , 2001 , 35, 783-4	2.9	22
10	Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 929-35 ^{6.1}		16
9	Portal hypertension and refractory ascites associated with multicentric Castleman disease. <i>Digestive Diseases and Sciences</i> , 2000 , 45, 697-702	4	3
8	Trovafloxacin-induced acute hepatitis. <i>Clinical Infectious Diseases</i> , 2000 , 30, 400-1	11.6	77
7	Fatal hepatitis associated with nimesulide. <i>Journal of Hepatology</i> , 2000 , 32, 174	13.4	24
6	Acute liver failure after treatment with nefazodone. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 2577-9	4	27
5	Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. <i>Journal of Hepatology</i> , 1999 , 31, 641-6	13.4	45
4	Severe idiosyncratic acute hepatic injury caused by paracetamol. <i>Journal of Hepatology</i> , 1998 , 28, 1078	13.4	12
3	Norfloxacin-induced cholestatic jaundice. <i>American Journal of Gastroenterology</i> , 1998 , 93, 2309-11	0.7	19
2	Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. <i>Journal of Hepatology</i> , 1995 , 22, 189-96	13.4	27
1	Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. <i>Drug and Alcohol Dependence</i> , 1990 , 26, 161-8	4.9	3